


Health Plan Coverage Report Card | March 2018

Mississippi Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Mississippi from January 2017 through December 2017.

Key Mississippi Findings



Rejection Rate:

31%



Appeals Rate:

19%



Final Rejections:

742

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- BCBS Mississippi **97%**
- Express Scripts **79%**
- State of Mississippi Employees **94%**
- United Health Group **45%**

The following had **the lowest rates of rejection:**

- Humana Health Plan **14%**
- WellDyneRx **0%**



The following table details claims data for the Mississippi managed care organizations that received at least 50 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
BCBS MS	97%	69	67
State Of Mississippi Employees	94%	54	51
Express Scripts	79%	52	41
United Health Group	45%	250	112
CVS Health	31%	326	100
Cigna Healthcare	30%	70	21
Aetna	25%	150	37
Wellcare Management Group	19%	163	31
Humana Health Plan	14%	734	100
WellDyneRx	0%	175	0

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

